XTX Topco Ltd Makes New Investment in Enovis Corporation $ENOV

XTX Topco Ltd bought a new stake in Enovis Corporation (NYSE:ENOV) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 74,295 shares of the company’s stock, valued at approximately $2,330,000.

A number of other large investors also recently modified their holdings of ENOV. Humankind Investments LLC grew its stake in Enovis by 8.6% in the first quarter. Humankind Investments LLC now owns 5,688 shares of the company’s stock valued at $217,000 after purchasing an additional 452 shares in the last quarter. US Bancorp DE grew its position in shares of Enovis by 2.5% in the first quarter. US Bancorp DE now owns 19,031 shares of the company’s stock valued at $727,000 after purchasing an additional 462 shares during the last quarter. Leisure Capital Management increased its position in Enovis by 2.2% during the 1st quarter. Leisure Capital Management now owns 22,903 shares of the company’s stock worth $875,000 after buying an additional 489 shares during the period. Teacher Retirement System of Texas raised its stake in Enovis by 6.1% in the 2nd quarter. Teacher Retirement System of Texas now owns 8,664 shares of the company’s stock worth $272,000 after purchasing an additional 495 shares in the last quarter. Finally, Wedge Capital Management L L P NC boosted its stake in shares of Enovis by 0.3% in the second quarter. Wedge Capital Management L L P NC now owns 162,977 shares of the company’s stock valued at $5,111,000 after buying an additional 498 shares during the period. 98.45% of the stock is currently owned by institutional investors and hedge funds.

Enovis Stock Down 0.4%

NYSE:ENOV opened at $30.32 on Thursday. Enovis Corporation has a one year low of $25.47 and a one year high of $49.75. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.25 and a quick ratio of 1.15. The company has a market cap of $1.73 billion, a PE ratio of -2.13 and a beta of 1.67. The firm’s 50 day simple moving average is $30.80 and its 200 day simple moving average is $31.03.

Enovis (NYSE:ENOV) last issued its quarterly earnings results on Monday, January 8th. The company reported $0.59 EPS for the quarter. Enovis had a negative net margin of 37.80% and a positive return on equity of 6.78%. The company had revenue of $383.81 million for the quarter. On average, research analysts anticipate that Enovis Corporation will post 2.79 earnings per share for the current year.

Analyst Upgrades and Downgrades

ENOV has been the subject of a number of analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enovis in a research note on Wednesday, October 8th. Needham & Company LLC decreased their target price on shares of Enovis from $57.00 to $49.00 and set a “buy” rating on the stock in a report on Thursday, August 7th. UBS Group cut their price target on shares of Enovis from $65.00 to $57.00 and set a “buy” rating for the company in a report on Friday, August 8th. Canaccord Genuity Group reduced their price target on shares of Enovis from $70.00 to $58.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. Finally, Wells Fargo & Company boosted their price objective on shares of Enovis from $41.00 to $42.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $51.17.

Insider Activity at Enovis

In related news, CEO Damien Mcdonald purchased 6,457 shares of Enovis stock in a transaction on Thursday, September 11th. The shares were purchased at an average price of $30.97 per share, for a total transaction of $199,973.29. Following the transaction, the chief executive officer owned 102,753 shares of the company’s stock, valued at approximately $3,182,260.41. This represents a 6.71% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 2.70% of the company’s stock.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.